| 产品详情 |
| Edit |   |
|---|
| Product Name | JNJ-26481585 |
|---|
| Description | Purity >98%. JNJ-26481585 is a hydroxamate-based HDAC inhibitor that shows activity toward all HDAC enzymes with highest potency in vitro toward HDAC1 (IC50 = 0.11 nM). For other HDACs, IC50 values range from 0.33, 0.37, and 0.46 nM for HDACs 2, 11, and 10, respectively, to 32, 77, and 119 nM for HDACs 9, 6, and 7, respectively. JNJ-26481585 induces apoptosis and cell cycle arrest in multiple myeloma cells and complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma or multiple myeloma xenografts. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | N-hydroxy-2-[4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide, Quisinostat |
|---|
| Gene, Accession, CAS # | CAS: 875320-29-9 |
|---|
| Catalog # | LS-H8293 |
|---|
| Price | |
|---|
| Order / More Info | JNJ-26481585 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|